Spots Global Cancer Trial Database for Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Official Title: A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Study ID: NCT03123588
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic, Phoenix, Arizona, United States
Pacific Shores Medical Group, Long Beach, California, United States
University of Southern California, Los Angeles, California, United States
Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
Compassionate Cancer Care Medical Group, Riverside, California, United States
Innovative Clinical Research Institute, Whittier, California, United States
Bond Clinic, PA, Winter Haven, Florida, United States
Tift Regional, Tifton, Georgia, United States
Edward Cancer Center, Naperville, Illinois, United States
North Shore Cancer Research Association-Skokie, Skokie, Illinois, United States
Southern Illinois University, Springfield, Illinois, United States
Clinical Trials of SWLA LLC, Lake Charles, Louisiana, United States
St. Agnes Hospital, Baltimore, Maryland, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Summit Medical Group, Morristown, New Jersey, United States
Montefiore Medical Center, Bronx, New York, United States
Columbia Weill Cornell Cancer Centers - Herbert Irving Comprehensive Cancer Center (HICCC), New York, New York, United States
Waverly Hem Onc, Cary, North Carolina, United States
Vidant Medical Center, Greenville, North Carolina, United States
Gabrail Cancer Center- Canton Facility, Canton, Ohio, United States
INTEGRIS Southwest Medical Center, Oklahoma City, Oklahoma, United States
INTEGRIS Cancer Institute Proton Campus, Oklahoma City, Oklahoma, United States
Kaiser Permanente Northwest, Portland, Oregon, United States
Geisinger - Knapper Clinic, Danville, Pennsylvania, United States
Prairie Lakes Health Care System Inc., Watertown, South Dakota, United States
Renovatio Clinical, The Woodlands, Texas, United States
Contact Details
Name: Albert Assad, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
